文献速递造血干细胞移植与细胞治疗白血病

造血干细胞支持治疗用于CAR-T细胞治疗后持续性中性粒细胞减少:一项GLA/DRST研究

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study.
PubMed 文献 · Blood Adv · 2023-01-01

该研究纳入31例CAR-T治疗后持续性中性粒细胞减少患者,接受造血干细胞支持治疗(30例自体、1例异基因)。中位应答时间9天,总中性粒细胞应答率84%,应答与既往中性粒细胞减少持续时间显著相关(P=.007),1年总生存率59%。

要点

  • 31例CAR-T后持续性中性粒细胞减少患者接受造血干细胞支持治疗,总应答率84%。
  • 中位应答时间9天(95%CI 7-14),应答与既往中性粒细胞减少持续时间相关(P=.007)。
  • 1年总生存率59%,中性粒细胞减少≤38天者85% vs >38天者44%(P=.029)。

核心结论

  • 早期或预防性造血干细胞支持治疗对CAR-T后持续性中重度中性粒细胞减少显示出快速应答并改善结局。

研究设计与样本

  • 该研究纳入31例接受造血干细胞支持治疗的患者,其中30例为自体、1例为异基因。
  • 适应证为持续性4级重度中性粒细胞减少(<0.5 × 10^9/L)、持续性中度中性粒细胞减少(≤1.5 × 10^9/L)且感染高风险,或中性粒细胞计数≤2.0 × 10^9/L且存在活动性感染。
  • CAR-T治疗至造血干细胞支持治疗的中位时间为43天,支持治疗时中位中性粒细胞绝对计数为0.2。
  • 支持治疗前中性粒细胞减少的中位持续时间为38天(范围7-151天)。

主要发现

  • 26例患者(84%)在中位9天(95%CI 7-14)内观察到总体中性粒细胞应答(恢复或改善)。
  • 应答时间与既往中性粒细胞减少持续时间显著相关(P=.007)。
  • 所有无应答者在造血干细胞支持治疗后第一年内死亡。
  • 全部患者1年总生存率为59%,中性粒细胞减少≤38天者为85% vs >38天者为44%(P=.029),差异显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematotoxicity after chimeric antigen receptor (CAR) T-cell therapy is associated with infection and death but management remains unclear. We report results of 31 patients receiving hematopoietic stem cell boost (HSCB; 30 autologous, 1 allogeneic) for either sustained severe neutropenia of grade 4 (<0.5 × 109/L), sustained moderate neutropenia (≤1.5 × 109/L) and high risk of infection, or neutrophil count ≤2.0 × 109/L and active infection. Median time from CAR T-cell therapy to HSCB was 43 days and median absolute neutrophil count at time of HSCB was 0.2. Median duration of neutropenia before HSCB was 38 days (range, 7-151). Overall neutrophil response rate (recovery or improvement) was observed in 26 patients (84%) within a median of 9 days (95% confidence interval, 7-14). Time to response was significantly associated with the duration of prior neutropenia (P = .007). All nonresponders died within the first year after HSCB. One-year overall survival for all patients was 59% and significantly different for neutropenia (≤38 days; 85%) vs neutropenia >38 days before HSCB (44%; P = .029). In conclusion, early or prophylactic HSCB showed quick response and improved outcomes for sustained moderate to severe neutropenia after CAR-T.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gagelmann N, Wulf GG, Duell J, et al. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study. Blood Adv. 2023. PMID: 35696759. doi:10.1182/bloodadvances.2022008042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。